Search

ACADIA Pharmaceuticals Inc

Suletud

SektorTervishoid

27.11 -0.95

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.64

Max

27.29

Põhinäitajad

By Trading Economics

Sissetulek

32M

35M

Müük

40M

308M

P/E

Sektori keskmine

12.341

56.432

Aktsiakasum

0.18

Kasumimarginaal

11.41

Töötajad

796

EBITDA

25M

32M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+29.82% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

356M

4.7B

Eelmine avamishind

28.06

Eelmine sulgemishind

27.11

Uudiste sentiment

By Acuity

50%

50%

115 / 339 Pingereas Healthcare

ACADIA Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2026, 22:46 UTC

ACADIA Pharmaceuticals Inc is down in after-market trading, following earlier losses, and remains below its 20-day moving average amid stagnant U.S. industrial production.

17. sept 2026, 19:36 UTC

ACADIA Pharmaceuticals Inc shares fell sharply, pulling back from an early high and remaining 4.38% below its 20-day moving average.

16. sept 2026, 19:16 UTC

ACADIA Pharmaceuticals Inc shares are higher, reaching a notable peak in early afternoon, despite trading below its 20-day moving average.

14. sept 2026, 20:08 UTC

ACADIA Pharmaceuticals Inc shares are lower today, reflecting broader market declines amid rising crude oil prices and inflation concerns ahead of the Federal Reserve's decision.

9. sept 2026, 20:07 UTC

ACADIA Pharmaceuticals Inc shares are higher Wednesday, pulling back earlier in the session. Broader market context includes rising crude oil prices above $100.

8. sept 2026, 20:01 UTC

News

ACADIA Pharmaceuticals is lower today, driven by significant declines in the Biotechnology sub-sector, reversing recent higher closes since Friday.

3. sept 2026, 20:02 UTC

Social Media

ACADIA Pharmaceuticals shares are declining, despite Canaccord Genuity and UBS reiterating Buy ratings and raising price targets amid positive outlooks for its products.

2. sept 2026, 20:08 UTC

ACADIA Pharmaceuticals is higher today, driven by gains in biotechnology stocks. Earlier, the stock peaked above Tuesday's close before pulling back slightly.

1. sept 2026, 20:09 UTC

ACADIA Pharmaceuticals is lower in Tuesday trading, in line with broader market declines amid rising oil prices and increasing Treasury yields.

31. aug 2026, 21:01 UTC

ACADIA Pharmaceuticals is higher in after-market trading, reflecting a notable move since Monday's close amid broader market sentiment on potential interest rate hikes.

28. aug 2026, 20:07 UTC

News

ACADIA Pharmaceuticals received EU approval for DAYBU to treat Rett syndrome. Shares are declining despite this development, reflecting unusual volatility during Friday's session.

27. aug 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are trading lower in after-market hours, despite being above the 20-day moving average and near the upper end of its trading range.

26. aug 2026, 20:08 UTC

ACADIA Pharmaceuticals is trading lower amid a weaker market following inflation data that may influence future Federal Reserve policy decisions.

25. aug 2026, 20:07 UTC

News
Event

Analysts' upgrades boost ACADIA Pharmaceuticals, with Deutsche Bank raising its price target to $38 and Citigroup to $40 following DAYBUE's EU approval.

24. aug 2026, 20:06 UTC

News
Event

ACADIA Pharmaceuticals received European Commission approval for DAYBU, the first treatment for Rett syndrome in the EU. Shares are advancing during Monday's session.

21. aug 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher, recovering from an early dip. The move aligns with broader market trends following a surge in Bitcoin prices.

20. aug 2026, 20:01 UTC

ACADIA Pharmaceuticals shares are lower amid a broader decline in biotechnology stocks, with unusual volatility noted today and cumulative returns down since Wednesday.

19. aug 2026, 19:46 UTC

ACADIA Pharmaceuticals is trading higher, reflecting positive sentiment in the biotechnology sector amid declining bond yields and increased liquidity, despite a recent pullback.

18. aug 2026, 20:02 UTC

News

BMO maintained an Outperform rating on ACADIA Pharmaceuticals with a $36 price target, contributing to positive market sentiment and advancing shares today.

17. aug 2026, 23:06 UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

13. aug 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

12. aug 2026, 19:56 UTC

News

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

11. aug 2026, 19:36 UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

7. aug 2026, 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6. aug 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5. aug 2026, 20:02 UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4. aug 2026, 23:01 UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3. aug 2026, 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31. juuli 2026, 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30. juuli 2026, 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

Võrdlus sarnastega

Hinnamuutus

ACADIA Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

29.82% tõus

12 kuu keskmine prognoos

Keskmine 35.429 USD  29.82%

Kõrge 49 USD

Madal 25 USD

Põhineb 15 Wall Streeti analüütiku instrumendi ACADIA Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

11

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

115 / 339 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.